Literature DB >> 16311265

Up-regulation of hippocampal metabotropic glutamate receptor 5 in temporal lobe epilepsy patients.

Robbert G E Notenboom1, David R Hampson, Gerard H Jansen, Peter C van Rijen, Cees W M van Veelen, Onno van Nieuwenhuizen, Pierre N E de Graan.   

Abstract

Metabotropic glutamate receptors (mGluRs) are G protein-coupled receptors involved in the regulation of glutamatergic transmission. Recent studies indicate that excitatory group I mGluRs (mGluR1 and mGluR5) contribute to neurotoxicity and hyperexcitability during epileptogenesis. In this study, we examined the distribution of mGluR1alpha and mGluR5 immunoreactivity (IR) in hippocampal resection tissue from pharmaco-resistant temporal lobe epilepsy (TLE) patients. IR was detected with panels of receptor subtype specific antisera in hippocampi from TLE patients without (non-HS group) and with hippocampal sclerosis (HS group) and was compared with that of non-epileptic autopsy controls (control group). By immunohistochemistry and immunoblot analysis, we found a marked increase of mGluR5 IR in hippocampi from the non-HS compared with the control group. High mGluR5 IR was most prominent in the cell bodies and apical dendrites of hippocampal principal neurons and in the dentate gyrus molecular layer. In the HS group, this increase in neuronal mGluR5 IR was even more pronounced, but owing to neuronal loss the number of mGluR5-immunoreactive neurons was reduced compared with the non-HS group. IR for mGluR1alpha was found in the cell bodies of principal neurons in all hippocampal subfields and in stratum oriens and hilar interneurons. No difference in mGluR1alpha IR was observed between neurons in both TLE groups and the control group. However, owing to neuronal loss, the number of mGluR1alpha-positive neurons was markedly reduced in the HS group. The up-regulation of mGluR5 in surviving neurons is probably a consequence rather than a cause of the epileptic seizures and may contribute to the hyperexcitability of the hippocampus in pharmaco-resistant TLE patients. Thus, our data point to a prominent role of mGluR5 in human TLE and indicate mGluR5 signalling as potential target for new anti-epileptic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16311265     DOI: 10.1093/brain/awh673

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  31 in total

1.  In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688.

Authors:  David Elmenhorst; Luciano Minuzzi; Antonio Aliaga; Jared Rowley; Gassan Massarweh; Mirko Diksic; Andreas Bauer; Pedro Rosa-Neto
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-09       Impact factor: 6.200

2.  Metabotropic glutamate receptor mGluR5 is not involved in the early hemodynamic response.

Authors:  Novella Calcinaghi; Renaud Jolivet; Matthias T Wyss; Simon M Ametamey; Fabrizio Gasparini; Alfred Buck; Bruno Weber
Journal:  J Cereb Blood Flow Metab       Date:  2011-07-06       Impact factor: 6.200

3.  Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection.

Authors:  Qiongman Kong; Ling-Chu Chang; Kou Takahashi; Qibing Liu; Delanie A Schulte; Liching Lai; Brian Ibabao; Yuchen Lin; Nathan Stouffer; Chitra Das Mukhopadhyay; Xuechao Xing; Kathleen I Seyb; Gregory D Cuny; Marcie A Glicksman; Chien-Liang Glenn Lin
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

Review 4.  Disease modification in epilepsy: from animal models to clinical applications.

Authors:  Melissa L Barker-Haliski; Dan Friedman; Jacqueline A French; H Steve White
Journal:  Drugs       Date:  2015-05       Impact factor: 9.546

5.  PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Dan Li; Hong Shan; Peter Conti; Zibo Li
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

6.  Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [(11)C]ABP688 PET.

Authors:  Jonathan M DuBois; Olivier G Rousset; Jared Rowley; Manuel Porras-Betancourt; Andrew J Reader; Aurelie Labbe; Gassan Massarweh; Jean-Paul Soucy; Pedro Rosa-Neto; Eliane Kobayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-21       Impact factor: 9.236

Review 7.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

8.  Positive modulation of mGluR5 attenuates seizures and reduces TNF-α+ macrophages and microglia in the brain in a murine model of virus-induced temporal lobe epilepsy.

Authors:  Tyler J Hanak; Jane E Libbey; Daniel J Doty; Jordan T Sim; Ana Beatriz DePaula-Silva; Robert S Fujinami
Journal:  Exp Neurol       Date:  2018-10-11       Impact factor: 5.330

9.  Arterial spin labeling demonstrates that focal amygdalar glutamatergic agonist infusion leads to rapid diffuse cerebral activation.

Authors:  J P Munasinghe; M Banerjee; M T Acosta; M Banks; A Heffer; A C Silva; A Koretsky; W H Theodore
Journal:  Acta Neurol Scand       Date:  2009-11-25       Impact factor: 3.209

Review 10.  Metabotropic glutamate receptor 5 - a promising target in drug development and neuroimaging.

Authors:  Rajapillai L I Pillai; Dnyanesh N Tipre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.